Correlation between a pollen challenge chamber and a natural allergen exposure study design for eliciting ocular and nasal symptoms: Early evidence supporting a paradigm shift in drug investigation?

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 1, 2012, Pages 128-129

  Bernstein, Jonathan A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

allergic rhinitis; endotypes; environmental exposure unit; natural season; Pollen challenge chamber; ragweed

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; PLACEBO;

AIR POLLUTANT; ASTHMA; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL EXPOSURE UNIT; HAY FEVER; HUMAN; IMMUNOTHERAPY; PHENOTYPE; POLLEN; PRIORITY JOURNAL; STANDARDIZATION; STUDY DESIGN; TREATMENT RESPONSE;

AMBROSIA; CONJUNCTIVITIS, ALLERGIC; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SEASONS;

EID: 84862841289     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.05.032     Document Type: Editorial

References (15)

1. J.H. Day, M. Briscoe, E. Rafeiro, D. Chapman, and B. Kramer Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system Ann Allergy Asthma Immunol 87 2001 474 481 (Pubitemid 34001035)
2. J.H. Day, M. Briscoe, and M.D. Widlitz Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit J Allergy Clin Immunol 101 1998 638 645 (Pubitemid 28228308)
3. J.H. Day, M.P. Briscoe, R.H. Clark, A.K. Ellis, and P. Gervais Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis Ann Allergy Asthma Immunol 79 1997 163 172 (Pubitemid 27375291)
4. J.H. Day, M.P. Briscoe, E. Rafeiro, A.K. Ellis, E. Pettersson, and A. Akerlund Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model J Allergy Clin Immunol 105 2000 489 494 (Pubitemid 30169906)
5. J.H. Day, M.P. Briscoe, A. Welsh, J.N. Smith, A. Clark, A.K. Ellis, and J. Mason Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit Ann Allergy Asthma Immunol 79 1997 533 540 (Pubitemid 28041818)
6. J.H. Day, D.L. Buckeridge, R.H. Clark, M.P. Briscoe, and R. Phillips A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis J Allergy Clin Immunol 97 1996 1050 1057
7. J.P. Donovan, D.L. Buckeridge, M.P. Briscoe, R.H. Clark, and J.H. Day Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure Ann Allergy Asthma Immunol 77 1996 74 80 (Pubitemid 26324156)
8. A.K. Ellis, J.D. Ratz, A.G. Day, and J.H. Day Factors that affect the allergic rhinitis response to ragweed allergen exposure Ann Allergy Asthma Immunol 104 2010 293 298
9. J.H. Day, A.K. Ellis, E. Rafeiro, J.D. Ratz, and M.P. Briscoe Experimental models for the evaluation of treatment of allergic rhinitis Ann Allergy Asthma Immunol 96 2006 263 278 315 (Pubitemid 43277164)
10. R.L. Jacobs, N. Harper, W. He, C.P. Andrews, C.G. Rather, and D.A. Ramirez Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes J Allergy Clin Immunol 130 2012 122 127.e8
11. J. Corren, R.A. Wood, D. Patel, J. Zhu, A. Yegin, and G. Dhillon Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge J Allergy Clin Immunol 127 2011 398 405
12. A.M. Salapatek, P. Patel, G. Gopalan, and S.T. Varghese Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients Am J Rhinol Allergy 24 2010 433 438
13. P. Stubner, R. Zieglmayer, and F. Horak A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC) Curr Med Res Opin 20 2004 891 902 (Pubitemid 38821528)
14. Togias A. Asthma, Allergy, and Inflammation Branch, Division of Allergy, Immunology and Transplantation, NIAID/NIH. Environmental exposure units: clinical trial design for validation. Bethesda: National Institute for Allergy and Infectious Diseases/National Institutes of Health; 2010. p. 1-12.
15. J.A. Bernstein, A. Salapatek, J.S. Lee, V. Nelson, D. Wilson, and P. D'Angelo Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber Allergy Asthma Proc 33 2012 1 8.